Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 905 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR AI Model Identifies How Every Country Can Improve Its Cancer Outcomes January 14, 2026 Potential of NOTCH1 Mutation to Predict Anti-PD1 Treatment Outcomes in Patients... April 23, 2025 With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 Genetic Testing for Bladder Cancer: What People With Cancer and Their... March 23, 2023 Load more HOT NEWS New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer 10 Tips for National Cancer Prevention Month A radical project: video game design meets cancer research
